187 related articles for article (PubMed ID: 4084340)
1. Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
Gülker H; Thale J; Olbing B; Heuer H; Frenking B; Bender F
Arzneimittelforschung; 1985; 35(9):1387-93. PubMed ID: 4084340
[TBL] [Abstract][Full Text] [Related]
2. [Electrophysiologic and hemodynamic effects of the new anti-arrhythmia agent diprafenone].
Gülker H; Heuer H; Thale J; Behrenbeck T
Z Kardiol; 1987 Jul; 76(7):411-4. PubMed ID: 3673162
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the electrophysiologic, antiarrhythmic and haemodynamic profile of a new isoquinolinedione derivative.
Gülker H; Spyra W; Thale J; Krimphove F; Hübner A; Bender F
Arzneimittelforschung; 1987 Aug; 37(8):917-9. PubMed ID: 3675686
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic, haemodynamic and antiarrhythmic effects of the new class Ic agent 1-(2'-biphenyloxy)-2-tert.-butylamino-propanol-2-hydrochloride.
Chiladakis I; Hindricks G; Haverkamp W; Vogt J; Gülker H
Arzneimittelforschung; 1989 Sep; 39(9):1130-2. PubMed ID: 2590263
[TBL] [Abstract][Full Text] [Related]
5. [Ischemic disorders of cardiac rhythm: effects of the autonomic nervous system on electrophysiologic findings and pharmacotherapy].
Gülker H; Thale J
Z Kardiol; 1986; 75 Suppl 5():15-34. PubMed ID: 3825228
[TBL] [Abstract][Full Text] [Related]
6. Use of diprafenone, a new potent propafenone-analogue, in acute experimental myocardial ischaemia and infarction.
Thale J; Gülker H; Hindricks G; Haverkamp W; Bender F
Eur Heart J; 1987 Aug; 8 Suppl D():107-15. PubMed ID: 3678251
[TBL] [Abstract][Full Text] [Related]
7. [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].
Geibel A; Zehender M; Hohnloser S; Landsrath C; Meinertz T; Just H
Z Kardiol; 1988 Jul; 77(7):464-9. PubMed ID: 2463720
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiologic effects of asocainol, a new antiarrhythmic agent with predominant class I action.
Thale J; Gülker H; Hagemense B; Rose D; Haverkamp W; Frenking B
Arzneimittelforschung; 1987 Jan; 37(1):14-6. PubMed ID: 3566851
[TBL] [Abstract][Full Text] [Related]
9. [Comparative studies on the anti-arrhythmic and anti-fibrillatory effectiveness of verapamil and nifedipine following acute coronary artery occlusion and reperfusion].
Gülker H; Thale J; Brisse B; Bender F
Z Kardiol; 1984 Aug; 73(8):515-24. PubMed ID: 6495811
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy].
Heuer H; Gülker H; Hasfeld M; Frenking B; Behrenbeck T
Z Kardiol; 1987 Jul; 76(7):415-20. PubMed ID: 3673163
[TBL] [Abstract][Full Text] [Related]
11. The antiarrhythmic and hemodynamic actions of alpha, alpha-dimethyl-4-(alpha, alpha, beta, beta-tetrafluorophenethyl) benzylamine (MK-251).
Torchiana ML; Stone CA; Wenger HC; Evans R; Lagerquist B; O'Malley T
J Pharmacol Exp Ther; 1975 Aug; 194(2):415-26. PubMed ID: 1151767
[TBL] [Abstract][Full Text] [Related]
12. [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Manz M; Beermann J; Gerckens U; Lüderitz B
Z Kardiol; 1986 Dec; 75(12):757-63. PubMed ID: 3825226
[TBL] [Abstract][Full Text] [Related]
13. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
14. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
[TBL] [Abstract][Full Text] [Related]
15. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.
Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S
Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477
[TBL] [Abstract][Full Text] [Related]
16. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
Brown BS; Calzadilla SV; Diemer MJ; Hartman JC; Reynolds RD
J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic, antiarrhythmic and cardiovascular actions of UM301, a quaternary ammonium compound.
Gibson JK; Patterson E; Lucchesi BR
J Pharmacol Exp Ther; 1986 Apr; 237(1):318-25. PubMed ID: 3754279
[TBL] [Abstract][Full Text] [Related]
18. [Electrophysiological effects of the antiarrhythmia agents disopyramide and propafenone on human heart conduction system].
Seipel L; Breithardt G; Both A
Z Kardiol; 1975 Aug; 64(8):731-40. PubMed ID: 1163095
[TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic, hemodynamic and cardiac electrophysiological evaluation of N-(2,6-dimethylphenyl)-N'-[3-(1-methylethylamino)propyl]urea (Wy-42,362).
Bergey JL; Sulkowski T; Much DR; Wendt RL
Arzneimittelforschung; 1983; 33(9):1258-68. PubMed ID: 6685506
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
Follath F; Candinas R; Frielingsdorf J
Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
